Stimulated Cellular Immune System in Patients with Congestive Heart Failure by Fuchs, D. et al.
Fuchs et al.: Stimulated cellular immunity in congestive heart failure 111
Eur. J. Clin. Chcm. Clin. Biochem.
Vol. 31, 1993, pp. 111-114
© 1993 Walter de Gruyter & Co.
Berlin · New York
Stimulated Cellular Immune System in Patients
with Congestive Heart Failure1)
By D. Fuchs1. M. Samsonov2, G. P. Tilz3, G. Reibnegger1, /. N. Belenkov2, E. L. Nassonov2 and H. W chter1
1 Institut f r Medizinische Chemie und Biochemie, Universit t Innsbruck, Austria
2 Institute for Clinical Cardiology, Cardiology Research Center, Moscow, Russia
3 Universit tsklinik fur Interne Medizin. Graz, Austria
(Received October 16, 1992)
Summary: In this cross-sectional study, we analysed serum concentrations of soluble markers of cellular
immune activation, namely, interferon-γ, neopterin (a product of activated macrophages), soluble interleukin-2
receptor, and soluble CDS, in 25 patients with congestive heart failure. Ten (40%) patients showed increased
concentrations (i.e. above the reference ranges of healthy controls) of neopterin, 14 (56%) showed increased
soluble interleukin-2 receptor, and 6 (24%) showed increased soluble CDS. Endogenous interferon-γ was
detectable in 10 patients (40%). In addition, we found significant correlations between neopterin and interferon-γ
(rs = 0.417, p < 0.05), and between neopterin and soluble CDS concentrations (rs = 0.430, p < 0.05). All
patients with increased soluble CDS also had increased soluble interleukin-2 receptor. However, no significant
correlations of soluble interleukin-2 receptor with soluble CDS or any of the other quantities were observed.
Increased concentrations of soluble interleukin-2 receptors, soluble CDS and neopterin indicate that cellular
immunity is stimulated in patients with congestive heart failure. Activated CDS-positive T-lymphocytes may
represent the source of increased soluble CDS. Endogenous interferon-γ, which is derived from activated T-
cells, may induce neopterin release by monocytes/macrophages.
Introduction , . , , . , . „ r 4 . , , 4derived biosynthetically from guanosine tnphosphate,
Patients with congestive heart failure often present are released from human macrophages on stimulation
with immunological abnormalities (1 —3). Viral infec- with interferon-γ (10). Increased neopterin concentra-
tions or autoimmune phenomena appear to be in- tions were observed earlier in patients suffering from
volved in the pathogenesis of the disorder (4, 5). diseases which involve activation of the cellular im-
Serologic evidence of persistent enterovirus infection mune system, such as viral infections, allograft rejee-
and enterovirus-specific RNA sequences can be found tion, and autoimmune diseases (10, 11). Also, in these
in myocardial biopsies of patients with myocarditis clinical conditions, increased neopterin may indicate
and dilated cardiomyopathy (6, 7). the increased endogenous formation of interferon-γ,
~ 4l , ., , . , . «.. r because significant correlations between the concen-Recently we described increased concentrations of . r. t f „«. . . *· *" -*u u · j·*· trationsof those two compounds are frequently foundserum neopterin in patients with chronic myocarditis t\^ \-\\
and dilated cardiomyopathy (8, 9). Large amounts of ^ J '"
neopterin, which is a pyrazino-pyrimidine-derivative In this study, we tried to gain further evidence for
cellular immune activation in patients with congestive
heart failure. We examined serum concentrations of
7 ~ I 7 " . r *u «Λ · u· u r» Λ interferon-γ, neopterin, and additional immune acti-') Supported by a grant from the " sterreichisches Bundes- . ί , , , t . ~
ministerium f r Wissenschaft und Forschung", Sektion For- vation markers, such as soluble interleukin-2 receptor
schung. and soluble CDS in the serum of patients.
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Patients and Methods
Ten male patients (mean age 42 + 11 years) with dilated
cardiomyopathy according to World Health Organization cri-
teria (14), and 15 patients with chronic myocarditis (14 males,
one female, mean age 35 ± 13 years), referred'to the Cardiology
Research Centre were studied. Eighteen patients underwent
coronary angiography, none had significant coronary artery
disease; endomyocardial biopsy was performed in 15 of the 18
patients. In one patient diagnosis was confirmed at necropsy.
Eleven patients had histological evidence of chronic myocar-
ditis. Clinically significant thromboembolic events were docu-
mented in eight patients.
Serum concentrations of neopterin were determined with a
commercially available readioimmunoassay (IMMUtest, Hen-
ning, Berlin, Germany), using standard protocols provided by
the manufacturer. Interferon-γ was quantified by radioimmu-
noassay (Centocor, Malvern, PA), employing an optimized ap-
plication that allows detection of interferon-γ with enhanced
sensitivity (13, 15). This procedure includes two overnight in-
cubation steps, and increases the sensitivity of the assay to a
detection limit of 18 U/l. Radioactivity was counted with a
gamma counter (CliniGamma 1272; Wallac Oy, Turku, Fin-
land). Cell-free test enzyme immunoassays were used for meas-
urements of soluble interleukin-2 receptor and soluble CDS (T
Cell Sciences, Inc., Cambridge, MA) and quantification was
performed using an ELISA-reader (Anthos, Labtec Instru-
ments, Salzburg, Austria).
The concentrations of the analytes were compared with pre-
established reference ranges of healthy controls which were
provided by the manufacturers of the assays and proven by
determinations on healthy volunteers in our laboratories
(tab. 1).
Statistical evaluation was done by x*-test and Fishefs exact test
for group comparisons, and Spearmarfs rank correlation co-
efficients (rs) were computed to assess mutual associations be-
tween the biochemical results.
Results
Average serum concentrations of interferon-γ, neo-
pterin, soluble interleukin-2 receptor and soluble CDS
are listed in table 1. Serum neopterin, soluble inter-
leukin-2 receptor and soluble CDS were significantly
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Fig. 1. Serum concentrations of interferon-γ (a), neopterin (b),
soluble interleukin^2 receptor (c) and soluble CD8 (d)
in patients with congestive heart failure. Open circles
indicate interferon-γ values below the detection limits.
The reference range of serum interferon-γ extends from
undetectable to 100 U/l (13). The reference ranges of
neopterin, soluble interleukin-2 receptor and soluble
CD8 in healthy controls (95th percentiles), obtained
from earlier studies, are represented by the dotted areas
(11,16).
neopterin concentrations was above the upper limit
of normal range (95th percentile of healthy controls)
in ten patients (40%). Six patients (24%) had in-
creased sol ble CDS, and 14 (56%) had increased
soluble interleukin-2 receptor concentrations (fig. 1).
Tab. 1. Serum concentrations of interferon-γ, neopterin, soluble interleukin-2 receptor and soluble CDS in 25 patients with





























controls (11, 13, 16)
<100 <8.7 <450 <540
* significantly increased incidence of elevated concentrations compared with healthy controls (p < 0.001, %2-test)
** significantly different from healthy controls (p < 0.01, x*-test)
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Tab. 2. Correlations between serum concentrations of inter-
feron-γ, neopterin, soluble interleukin-2 receptor and
soluble CD8 (Spearman's rank correlation coefficients



















Endogenous interferon-γ was detectable in ten of 25
patients (40%). In one patient the serum concentra-
tions of interferon-γ was 428 U/l; this is well above
the upper limit of healthy controls which is 100 U/l.
Significant correlations were found between inter-
feron-γ and neopterin concentrations, and between
neopterin and soluble CD8 concentrations. No cor-
relations existed between the other variables measured
(tab. 2).
Seven of the ten patients with increased neopterin also
had increased interferon-γ concentrations, as had 3
of the 15 patients with normal neopterin (p = 0.02,
Fischer's exact test). All six patients with increased
soluble CDS had increased soluble interleukin-2 re-
ceptor, seven often patients with normal soluble CDS
also had increased soluble interleukin-2 receptor
(p = 0.01). Five of six patients with increased soluble
CDS had increased neopterin, but also six of 19 pa-
tients with normal soluble CDS had abnormal neop-
terin (p = not significant). There was no apparent
association between increased or decreased soluble
interleukin-2 receptor, and increased or decreased
neopterin and interferon-γ.
Discussion
This study shows that a significant percentage of a
panel of immune activation markers is elevated in
patients with congestive heart failure. Serum concen-
trations of neopterin, soluble interleukin-2 receptor
and soluble CDS were found to be increased in a
variable but significant proportion of patients.
In vitro and in vivo data demonstrated a strong
association between increased neopterin formation
and the activation of cell mediated immunity (10,11).
High neopterin concentrations are known to be
closely associated with endogenous formation of cy-
tokines during immune stimulation. Interferon-γ is
the most potent inducer of neopterin formation and
release by human monocytes/macrophages (11, 17).
Endogenous interferon-γ was detected in less than
half of the patients of this study. Although an opti-
mized protocol was used, the sensitivity of the inter-
feron-γ assay for the detection of immune activation
was much lower than that of the other quantities
measured in this study. Interferon-γ was outside the
normal range in only one patient, who also had the
highest neopterin concentration. Nevertheless, a sig-
nificant association between increased interferon-γ
and increased neopterin concentrations was found
(tab. 2). It is possible that interferon-γ is released at
local sites of inflammation and does not freely enter
the blood stream. Similar observations were made
earlier in patients with solid allograft rejections (18).
Interferon-γ may be released by activated T-cells and
induce neopterin formation by monocytes/macro-
phages. Increased concentrations of soluble interleu-
kin-2 receptor and soluble CDS found in some pa-
tients further support this conclusion. In vitro data
show soluble interleukin-2 receptor and soluble CDS
to be shed from activated and proliferating T-lym-
phocytes (19, 20). In the shedding of soluble interleu-
kin-2 receptor, it is not possible to distinguish between
the subpopulations of T-cells involved, but increased
soluble CDS concentrations point to a role of soluble
CDS-positive cytotoxic/suppressor cells. Thus, our re-
sults favour the view that activated cytotoxic T-lym-
phocytes play a role in the release of interferon-γ in
patients with congestive heart failure. In agreement
with this assumption a correlation was found between
soluble CDS and neopterin concentrations in the pa-
tients. Similar associations between the two quantities
have also been described in patients with human im-
munodeficiency virus (HIV) infection (21).
There were no strong correlations between soluble
interleukin-2 receptor and the other variables. Nota-
bly, in earlier investigations on patients with HIV
infection, the association between neopterin and sol-
uble interleukin-2 receptor concentrations was also
found to be rather weak (16, 22). The size of the study
is, however, too small for a final conclusion.
In earlier studies we found a significant association
between increased neopterin concentrations and the
stage of patients with congestive heart failure.(8). In
addition, several significant correlations were found
between functional tests of left ventricles (such as end-
diastolic volume and ejection fraction) and neopterin
concentrations (8, 9). The same abnormalities of left
ventricular quantities are significantly associated with
outcome in patients with dilated cardiomyopathy
(23). Thus, the correlations between neopterin con-
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centrations and other markers of immune stimulation
found in this study further support a potential asso-
ciation between immune activation and the pathogen-
esis of congestive heart failure.
Our study shows that activation of the cellular im-
mune system takes place in patients with congestive
heart failure. Virus infection and/or autoimmune dis-
ease or both are involved in the aetiology of myocar-
dial inflammation in patients with dilated cardiomyo-
pathy or chronic myocarditis, aild immune activation
may contribute to the spectrum of symptoms in pa-
tients and to progression of the disease.
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